Asahi Kasei has agreed to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million ($920.8 million). Aicuris adds three compounds that complement Asahi Kasei’s existing treatment portfolio and expand its presence in infectious diseases: Prevymis, Pritelivir and AIC468. This transaction is expected to close in the first quarter of fiscal 2026, subject to customary conditions. The acquisition advances Asahi Kasei’s...